NDAINHALATIONPOWDER
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
furoate, umeclidinium, and vilanterol. The mechanisms of action described below for the individual components apply to TRELEGY ELLIPTA. These drugs represent 3 different classes of medications (an ICS, an anticholinergic, and a LABA), each having different effects on clinical and physiological…
Indications (3)
Clinical Trials (1)
To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD
Started Oct 2022
463 enrolled
Pulmonary Disease, Chronic Obstructive
Loss of Exclusivity
LOE Date
Apr 11, 2031
62 months away
Patent Expiry
Apr 11, 2031
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7488827 | Dec 18, 2027 | SubstanceProduct | — |
| 8534281 | Mar 8, 2030 | Product | — |
| 8534281*PED | Sep 8, 2030 | — | |
| 8746242 | Oct 11, 2030 | Product | — |
| 9750726 | Nov 29, 2030 | Product | — |